Magic mushroom nasal spray

“I came a little late to the magic mushroom space as a user. I had no information about the medicinal benefits until I met a doctor while travelling in the spring of 2018 who blew my mind with research. It changed my life.”

Users of psychedelics have long argued small doses of mushrooms can offer spiritual and medical benefits without sending the user on a “trip”. Buy Magic mushroom nasal spray

Smart Shops: A Smart Move?

Per the deal, the companies will jointly build and operate a “smart shop” retail store offering tinctures, capsules, topicals, edibles and other mushroom-based products, as well as literature on the topic and related accessories. The psychedelic products will be supplied by Silo, which currently cultivates psilocybin mushrooms in Jamaica and is working on a nasal spray.

Oregon psychedelic startup tests Buy Magic mushroom nasal spray for PTSD, depression as legislative momentum builds

If you want to know just how quickly public sentiment around psychedelics is changing, consider this: Gwyneth Paltrow sent her staffers to psilocybin-assisted therapy in the first episode of the Netflix docu-series the Goop Lab. Meanwhile, billionaires attending the World Economic Forum in Davos heard a pitch from a company developing a hallucinogenic drug to treat opioid addiction. Buy Magic mushroom nasal spray

With Oregon activists pushing for state-wide decriminalization of magic mushrooms for therapeutic use this year, one local startup wants to keep the momentum going. Silo Wellness, based in Springfield, Oregon, has developed a nasal spray for microdosing psilocybin meant to aid with anxiety, PTSD and depression. The company now hopes to spread the good word, offering seminars for volunteers who normally wouldn’t try it on the black market to test the device in a controlled setting in Jamaica, where magic mushrooms are legal. Buy Magic mushroom nasal spray

“My hypothesis being that this has the best chance of catalyzing legalization in the United States, when people go back and tell their peers and friends on Facebook that they tried mushrooms,” Mike Arnold, a former trial attorney and the founder of Silo Wellness, said in January before the COVID-19 outbreak.

Arnold says his goal is to “get psychedelics in the hands of as many people as quickly and inexpensively as possible.”

Almost 50 years after President Richard Nixon launched an anti-drug crusade, a growing number of researchers, companies and institutions are betting that the long-shunned hallucinogens could be poised for growth amid rising scientific evidence for their efficacy in treating some of the toughest mental health and addiction challenges. Buy Magic mushroom nasal spray

Over 260 million people of all ages suffer from depression, which is a leading cause of disability worldwide, according to the World Health Organization. With the rise of awareness around mental health and mental illness, more startups are targeting the underserved market than ever before, says Stephen Hays, the founder of What If Ventures, which invests in early-stage mental health and addiction recovery focused companies.

More than 700 startups are building solutions for mental health and emotional well-being, with just over $4.5 billion invested, according to Hays’ estimates. About a dozen are focused on psychedelics, laying the groundwork in the anticipation of their removal from Schedule 1 category, which may happen in the next two years. Buy Magic mushroom nasal spray

RELATED: COVID-19 mental health crunch puts impetus on psychedelic drug innovation, doctor says

“Because the regulation is being crafted from scratch and the laws have to be changed, there are going to be a lot of people who start businesses and then get blindsided by the bureaucracy of the system,” said Hays. “It’s a really hard place to invest early without getting a little bit lucky.”

Earlier this month, the U.K.-based Compass Pathways, which is conducting the world’s first large-scale psilocybin therapy clinical trial, raised $80 million in a Series B round from investors, including ATAI Life Sciences, Founders Fund and Able Partners. The company, which holds a US patent relating to methods of treating drug-resistant depression “with a psilocybin formulation,” is also backed by Silicon Valley billionaire Peter Thiel, who has invested in other companies focused on psychedelics. Buy Magic mushroom nasal spray

Meanwhile, Johns Hopkins University and Imperial College London last year opened new research centers, with more than $20 million in commitments from wealthy private donors, to study compounds like LSD and psilocybin for mental health disorders, depression and addiction.

Psilocybin is officially listed as an “eligible investigation drug” for terminally ill patients under the Right to Try Act passed by President Trump in 2018. According to one study, most cancer patients experienced “significant decreases in depressed mood and anxiety” after a session, while two-thirds said it was among the most meaningful experiences of their lives. Buy Magic mushroom nasal spray

“For the first time in decades, psychiatry has a real shot at having approved treatments that not only alleviate the symptoms, but empower patients, and we simply cannot afford to miss that chance,” Ekaterina Malievskaia, chief innovation officer and co-founder of Compass Pathways wrote on LinkedIn in December. Magic mushroom nasal spray for depression